Genomics

Beam Therapeutics is set to announce its 2025 financial results and a new liver-targeted therapy, a key moment for its base editing platform and investors.

Acquiring Complete Genomics, Swiss Rockets unveils its CoolMPS 600, a bid to democratize long-read sequencing with breakthrough cost and accuracy.

New England Biolabs is launching next-gen sample prep tools, targeting long-read sequencing, RNA bias, and clinical epigenetics to accelerate discovery.

Element Biosciences unveils VITARI, a high-throughput benchtop sequencer promising a $100 whole genome, challenging market giants and democratizing genomics.

Watchmaker Genomics is repurposing CRISPR, not for editing genes, but to make DNA sequencing faster, cheaper, and more reliable than ever before.

A genomic test identifies which breast cancer patients truly benefit from extended hormone therapy, a major step toward personalized long-term care.

A new genomics tracker reveals the fragmented adoption of precision cancer care across the EU-5, highlighting critical barriers and strategic opportunities.

A new oral drug, IMSB301, offers hope for Aicardi Goutières Syndrome, a devastating rare disease with no cure, in a pivotal new clinical trial.

The French biopharma giant posts strong 2025 results and forecasts over 13% growth, fueled by a booming pipeline and unexpected market advantages.

Katherine Stueland’s honor underscores a major shift in healthcare, as genomic screening and AI promise to end the diagnostic odyssey for rare diseases.

UCLA's Dr. Donald Kohn joins the Jeffrey Modell Foundation to discuss revolutionary gene therapies offering new hope for Primary Immunodeficiency patients.

AI genomics firm partners with two major US health systems, aiming to accelerate cancer and rare disease diagnostics for 60,000 patients annually.

Amid major restructuring and a strategic asset sale, Standard BioTools' upcoming annual results will reveal its progress toward profitability in a tough market.

Waters finalized its $18.8B merger with BD's units, doubling its size. But investor concerns over near-term performance sent shares tumbling.

Bionano's 2026 virtual event will showcase how Optical Genome Mapping is revolutionizing cancer and genetic disease research and paving a path to clinical use.

Early trial data for ABX1100 reveals a novel approach to reducing muscle damage in Pompe disease, offering hope for less burdensome treatment.

The biotech celebrates its first FDA drug approval, a massive financial boost, and promising new therapies targeting obesity and Alzheimer's disease.

A new initiative unites top scientists to study 'SuperAgers' and resilient brains, aiming to unlock the secrets of healthy aging and prevent Alzheimer's.

VectorY Therapeutics adds seasoned biotech architect Kevin Pojasek to its board, signaling a strategic push to accelerate its novel therapies for ALS and Alzheimer's.

A new partnership will integrate data from millions in India and the UAE, aiming to fix research bias and build more equitable AI-driven medicine.